8-K: Lifecore Biomedical Files Restated 2023 Annual Report, Provides Supplemental Financial Data

Lifecore Biomedical has filed its restated Annual Report on Form 10-K for fiscal year 2023, including restatements for prior periods and providing supplemental financial information.

Summary

• Lifecore Biomedical has filed its Annual Report on Form 10-K for the fiscal year ended May 28, 2023, which includes restatements of previously issued financial statements.
• The restatements cover fiscal years 2021 and 2022, and also include adjustments to unaudited financial statements from 2020 to 2023.
• The errors corrected relate to the calculation of capitalized interest, valuation of inventories, and adjustments related to divested businesses.
• The company has also adjusted certain items previously deemed immaterial.
• Lifecore has provided a supplementary summary of select financial data to assist investors in analyzing the restated financials.
• The restatements primarily impact the Lifecore segment, with adjustments to inventories, cost of sales, property and equipment, interest expense, and revenue recognition.
• There were also restatements related to the former Curation Foods segment, affecting retained earnings and the presentation of operating costs.
• The company has provided non-GAAP financial measures, including EBITDA and adjusted EBITDA, to supplement its GAAP financials.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the need for significant restatements, which raises concerns about past financial reporting. However, the company is taking steps to correct the issues and move forward.

Positives

• The company has completed the restatement process and filed its 2023 annual report.
• Lifecore has provided supplemental financial information to help investors understand the restatements.
• The company is now focused on completing its First Quarter Fiscal 2024 Report on Form 10-Q.

Negatives

• The need for restatements indicates prior errors in financial reporting.
• The restatements involved multiple adjustments across several financial statement line items.
• The restatements include adjustments to both the Lifecore and former Curation Foods segments.

Risks

• The company's ability to become current with its SEC reports is a risk.
• There is a risk that the company may not regain compliance with Nasdaq listing standards.
• The company's strategic alternatives are under evaluation, which introduces uncertainty.
• The company's ability to expand its relationships with existing customers is a risk.

Future Outlook

The company is focused on completing its First Quarter Fiscal 2024 Report on Form 10-Q and is evaluating strategic alternatives.

Management Comments

• Management believes these non-GAAP financial measures provide useful additional information to investors about trends in the Company's operations and are useful for period-over-period comparisons.

Industry Context

Lifecore operates in the CDMO sector, which is experiencing growth due to increased outsourcing by pharmaceutical and biotech companies. The restatement does not appear to be related to industry specific issues.

Comparison to Industry Standards

• The restatement of financial results is not typical for established CDMO companies, which generally have robust internal controls.
• Companies like Catalent and Lonza, which are major players in the CDMO space, typically do not have such significant restatements.
• The issues identified, such as capitalized interest and inventory valuation, are fundamental accounting principles that are usually well-managed by public companies.
• The need for restatements may raise concerns about the company's internal controls and financial reporting processes compared to industry best practices.

Stakeholder Impact

• Shareholders may be concerned about the restatements and the potential impact on the company's valuation.
• Employees may be affected by the uncertainty surrounding the company's strategic alternatives.
• Customers may be concerned about the company's financial stability and ability to deliver services.

Next Steps

• The company will focus on completing its First Quarter Fiscal 2024 Report on Form 10-Q.
• The company will continue to evaluate strategic alternatives.

Key Dates

Keywords

restatement, financial statements, annual report, Form 10-K, EBITDA, adjusted EBITDA, Lifecore Biomedical, CDMO, inventories, capitalized interest